Henry Schein (HSIC) 10-Q 7 Aug 23 2023 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jul. 01, 2023	Jul. 31, 2023
Cover [Abstract]
Entity Central Index Key	0001000228
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-30
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jul. 01, 2023
Document Transition Report	false
Entity Registrant Name	HENRY SCHEIN, INC.
Entity File Number	0-27078
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3136595
Entity Address, Address Line One	135 Duryea Road
Entity Address, City or Town	Melville
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11747
City Area Code	631
Local Phone Number	843-5500
Title of 12(b) Security	Common Stock, par value $.01 per share
Trading Symbol	HSIC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		130,584,592

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Jul. 01, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 137	$ 117
Accounts receivable, net of allowance for credit losses of $70 and $65	1,468	1,442
Inventories, net	1,843	1,963
Prepaid expenses and other	463	466
Total current assets	3,911	3,988
Property and equipment, net	439	383
Operating lease right-of-use assets	290	284
Goodwill	3,335	2,893
Other intangibles, net	678	587
Investments and other	493	472
Total assets	9,146	8,607
Current liabilities:
Accounts payable	817	1,004
Bank credit lines	325	103
Current maturities of long-term debt	66	6
Operating lease liabilities	74	73
Accrued expenses:
Payroll and related	275	314
Taxes	129	132
Other	590	592
Total current liabilities	2,276	2,224
Long-term debt	1,133	1,040
Deferred income taxes	50	36
Operating lease liabilities	284	275
Other liabilities	397	361
Total liabilities	4,140	3,936
Redeemable noncontrolling interests	820	576
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.01 par value, 1,000,000 shares authorized, none outstanding	0	0
Common stock, $0.01 par value, 480,000,000 shares authorized,130,576,806 outstanding on July 01, 2023 and 131,792,817 outstanding on December 31, 2022	1	1
Additional paid-in capital	0	0
Retained earnings	3,769	3,678
Accumulated other comprehensive loss	(210)	(233)
Total Henry Schein, Inc. stockholders' equity	3,560	3,446
Noncontrolling interests	626	649
Total stockholders' equity	4,186	4,095
Total liabilities, redeemable noncontrolling interests and stockholders' equity	$ 9,146	$ 8,607

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Jul. 01, 2023	Dec. 31, 2022
Current assets:
Accounts receivable, allowances for credit losses (in dollars)	$ 70	$ 65
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	480,000,000	480,000,000
Common stock, shares outstanding (in shares)	130,576,806	131,792,817

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jun. 25, 2022	Jul. 01, 2023	Jun. 25, 2022
CONDENSED CONSOLIDATED STATEMENTS OF INCOME [Abstract]
Net sales	$ 3,100,000,000	$ 3,030,000,000	$ 6,160,000,000	$ 6,209,000,000
Cost of sales	2,125,000,000	2,085,000,000	4,219,000,000	4,291,000,000
Gross profit	975,000,000	945,000,000	1,941,000,000	1,918,000,000
Operating expenses:
Selling, general and administrative	707,000,000	680,000,000	1,424,000,000	1,362,000,000
Depreciation and amortization	49,000,000	45,000,000	93,000,000	92,000,000
Restructuring costs	18,000,000	0	48,000,000	0
Operating income	201,000,000	220,000,000	376,000,000	464,000,000
Other income (expense):
Interest income	3,000,000	2,000,000	6,000,000	4,000,000
Interest expense	(19,000,000)	(8,000,000)	(33,000,000)	(15,000,000)
Other, net	1,000,000	0	0	0
Income before taxes, equity in earnings of affiliates and noncontrolling interests	186,000,000	214,000,000	349,000,000	453,000,000
Income taxes	(41,000,000)	(52,000,000)	(80,000,000)	(109,000,000)
Equity in earnings of affiliates	3,000,000	5,000,000	7,000,000	9,000,000
Net income	148,000,000	167,000,000	276,000,000	353,000,000
Less: Net income attributable to noncontrolling interests	(8,000,000)	(7,000,000)	(15,000,000)	(12,000,000)
Net income attributable to Henry Schein, Inc.	$ 140,000,000	$ 160,000,000	$ 261,000,000	$ 341,000,000
Earnings per share attributable to Henry Schein, Inc.:
Basic (in dollars per share)	$ 1.07	$ 1.17	$ 1.99	$ 2.49
Diluted (in dollars per share)	$ 1.06	$ 1.16	$ 1.97	$ 2.46
Weighted-average common shares outstanding:
Basic (in shares)	130,905,899	137,350,488	131,136,450	137,323,076
Diluted (in shares)	131,873,174	138,869,064	132,465,749	139,055,205

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jun. 25, 2022	Jul. 01, 2023	Jun. 25, 2022
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME [Abstract]
Net income	$ 148	$ 167	$ 276	$ 353
Other comprehensive income (loss), net of tax:
Foreign currency translation gain (loss)	3	(90)	28	(87)
Unrealized gain (loss) from foreign currency hedging activities	(1)	8	(4)	9
Other comprehensive income (loss), net of tax	2	(82)	24	(78)
Comprehensive income	150	85	300	275
Less: Comprehensive income attributable to noncontrolling interests:
Net income	(8)	(7)	(15)	(12)
Foreign currency translation loss (gain)	1	9	(1)	8
Comprehensive (income) loss attributable to noncontrolling interests	(7)	2	(16)	(4)
Comprehensive income attributable to Henry Schein, Inc.	$ 143	$ 87	$ 284	$ 271

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Millions	Total	Common Stock $.01 Par Value [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Noncontrolling Interests [Member]
Beginning Balance at Dec. 25, 2021	$ 4,063	$ 1	$ 0	$ 3,595	$ (171)	$ 638
Beginning Balance, shares (in shares) at Dec. 25, 2021		137,145,558
Net income (excluding amounts attributable to redeemable noncontrolling interests)	344			341		3
Foreign currency translation gain (loss) (excluding loss amounts attributable to redeemable noncontrolling interests)	(80)				(79)	(1)
Unrealized gain (loss) from foreign currency hedging activities, net of tax	9				9
Purchase of noncontrolling interests	(7)					(7)
Change in fair value of redeemable noncontrolling interests	7		7
Repurchases and retirement of common stock - Value	(110)		(16)	(94)
Repurchases and retirement of common stock - Shares		(1,345,397)
Stock-based compensation expense - Value	27		27
Stock-based compensation expense - Shares		954,899
Stock issued upon exercise of stock options - Value	2		2
Stock issued upon exercise of stock options - Shares		29,827
Shares withheld for payroll taxes - Value	(29)		(29)
Shares withheld for payroll taxes - Shares		(342,347)
Settlement of stock-based compensation awards - Value	1		1
Settlement of stock-based compensation awards - Shares		(2,980)
Transfer of charges in excess of capital			8	(8)
Ending Balance at Jun. 25, 2022	4,227	$ 1	0	3,834	(241)	633
Ending Balance, shares (in shares) at Jun. 25, 2022		136,439,560
Beginning Balance at Mar. 26, 2022	4,224	$ 1	0	3,759	(168)	632
Beginning Balance, shares (in shares) at Mar. 26, 2022		137,708,809
Net income (excluding amounts attributable to redeemable noncontrolling interests)	162			160		2
Foreign currency translation gain (loss) (excluding loss amounts attributable to redeemable noncontrolling interests)	(82)				(81)	(1)
Unrealized gain (loss) from foreign currency hedging activities, net of tax	8				8
Change in fair value of redeemable noncontrolling interests	10		10
Repurchases and retirement of common stock - Value	(110)		(16)	(94)
Repurchases and retirement of common stock - Shares		(1,345,397)
Stock-based compensation expense - Value	15		15
Stock-based compensation expense - Shares		78,738
Stock issued upon exercise of stock options - Shares		3,594
Shares withheld for payroll taxes - Value	(1)		(1)
Shares withheld for payroll taxes - Shares		(6,016)
Settlement of stock-based compensation awards - Value	1		1
Settlement of stock-based compensation awards - Shares		(168)
Transfer of charges in excess of capital			(9)	(9)
Ending Balance at Jun. 25, 2022	4,227	$ 1	0	3,834	(241)	633
Ending Balance, shares (in shares) at Jun. 25, 2022		136,439,560
Beginning Balance at Dec. 31, 2022	$ 4,095	$ 1	0	3,678	(233)	649
Beginning Balance, shares (in shares) at Dec. 31, 2022	131,792,817	131,792,817
Net income (excluding amounts attributable to redeemable noncontrolling interests)	$ 267			261		6
Foreign currency translation gain (loss) (excluding loss amounts attributable to redeemable noncontrolling interests)	27				27
Unrealized gain (loss) from foreign currency hedging activities, net of tax	(4)				(4)
Dividends declared	(27)					(27)
Change in fair value of redeemable noncontrolling interests	(14)		(14)
Initial noncontrolling interests and adjustments related to business acquisitions	(1)		1			(2)
Repurchases and retirement of common stock - Value	(151)		(20)	(131)
Repurchases and retirement of common stock - Shares		(1,862,014)
Stock-based compensation expense - Value	24		24
Stock-based compensation expense - Shares		1,036,898
Stock issued upon exercise of stock options - Value	$ 1		1
Stock issued upon exercise of stock options - Shares	17,905	15,860
Shares withheld for payroll taxes - Value	$ (32)		(32)
Shares withheld for payroll taxes - Shares		(405,865)
Settlement of stock-based compensation awards - Value	1		1
Settlement of stock-based compensation awards - Shares		(890)
Transfer of charges in excess of capital			39	(39)
Ending Balance at Jul. 01, 2023	$ 4,186	$ 1	0	3,769	(210)	626
Ending Balance, shares (in shares) at Jul. 01, 2023	130,576,806	130,576,806
Beginning Balance at Apr. 01, 2023	$ 4,127	$ 1	0	3,684	(213)	655
Beginning Balance, shares (in shares) at Apr. 01, 2023		131,196,783
Net income (excluding amounts attributable to redeemable noncontrolling interests)	143			140		3
Foreign currency translation gain (loss) (excluding loss amounts attributable to redeemable noncontrolling interests)	4				4
Unrealized gain (loss) from foreign currency hedging activities, net of tax	(1)				(1)
Dividends declared	(27)					(27)
Change in fair value of redeemable noncontrolling interests	(17)		(17)
Initial noncontrolling interests and adjustments related to business acquisitions	(4)		1			(5)
Repurchases and retirement of common stock - Value	(51)		(7)	(44)
Repurchases and retirement of common stock - Shares		(638,095)
Stock-based compensation expense - Value	14		14
Stock-based compensation expense - Shares		20,598
Stock issued upon exercise of stock options - Shares		5,081
Shares withheld for payroll taxes - Value	(3)		(3)
Shares withheld for payroll taxes - Shares		(6,671)
Settlement of stock-based compensation awards - Value	1		1
Settlement of stock-based compensation awards - Shares		890
Transfer of charges in excess of capital			11	(11)
Ending Balance at Jul. 01, 2023	$ 4,186	$ 1	$ 0	$ 3,769	$ (210)	$ 626
Ending Balance, shares (in shares) at Jul. 01, 2023	130,576,806	130,576,806

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jul. 01, 2023	Jun. 25, 2022	Jul. 01, 2023	Jun. 25, 2022	Dec. 31, 2022
Net income attributable to redeemable noncontrolling interests	$ 5	$ 5	$ 9	$ 9	$ 21
Foreign currency translation gain (loss) attributable to redeemable noncontrolling interests	(1)	(8)	1	7	$ (6)
Unrealized gain (loss) from foreign currency hedging activities, tax (benefit)	$ (1)	$ 2	$ (2)	$ 3

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	6 Months Ended
	Jul. 01, 2023	Jun. 25, 2022
Cash flows from operating activities:
Net income	$ 276	$ 353
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	111	108
Non-cash restructuring charges	10	0
Stock-based compensation expense	24	27
Provision for losses on trade and other accounts receivable	2	0
Benefit from deferred income taxes	(3)	(15)
Equity in earnings of affiliates	(7)	(9)
Distributions from equity affiliates	9	10
Changes in unrecognized tax benefits	3	(1)
Other	(9)	(13)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	18	21
Inventories	163	4
Other current assets	(1)	(37)
Accounts payable and accrued expenses	(295)	(198)
Net cash provided by operating activities	301	250
Cash flows from investing activities:
Purchases of fixed assets	(68)	(43)
Payments related to equity investments and business acquisitions, net of cash acquired	(251)	(7)
Proceeds from loan to affiliate	3	6
Other	(24)	(15)
Net cash used in investing activities	(340)	(59)
Cash flows from financing activities:
Net change in bank borrowings	218	30
Proceeds from issuance of long-term debt	408	0
Principal payments for long-term debt	(366)	(57)
Proceeds from issuance of stock upon exercise of stock options	1	2
Payments for repurchases and retirement of common stock	(150)	(110)
Payments for taxes related to shares withheld for employee taxes	(33)	(29)
Distributions to noncontrolling shareholders	(6)	(12)
Acquisitions of noncontrolling interests in subsidiaries	(13)	(19)
Net cash provided by (used in) financing activities	59	(195)
Effect of exchange rate changes on cash and cash equivalents	0	(6)
Net change in cash and cash equivalents	20	(10)
Cash and cash equivalents, beginning of period	117	118
Cash and cash equivalents, end of period	$ 137	$ 108

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jul. 01, 2023
Basis of Presentation [Abstract]
Basis of Presentation	Note 1 – Basis of Presentation Our condensed consolidated financial statements include the accounts of Henry controlled subsidiaries (“we”, “us” or “our”). consolidation. financial decisions are accounted for under the equity method. to conform to the current period presentation. have a material impact on our condensed consolidated financial condition, Our accompanying unaudited condensed consolidated financial statements accounting principles generally accepted in the United States with the instructions to Form 10-Q and Article 10 of Regulation S-X. information and footnote disclosures required by U.S. GAAP for complete financial The unaudited interim condensed consolidated financial statements should be consolidated financial statements and notes to the consolidated financial on Form 10-K for the year ended December 31, 2022 and with the information available filings with the Securities and Exchange Commission. reflect all adjustments considered necessary for a fair presentation of the financial position for the interim periods presented. The preparation of financial statements in conformity with accounting principles States requires us to make estimates and assumptions that affect the reported amounts of disclosure of contingent assets and liabilities at the date of the financial statements revenues and expenses during the reporting period. operations for the three and six months ended July 1, 2023 are not necessarily expected for any other interim period or for the year ending December Our condensed consolidated financial statements reflect estimates and other things, our goodwill, long-lived asset and definite-lived intangible investment valuation; assessment of the annual effective tax rate; valuation of tax contingencies; the allowance for doubtful accounts; hedging activity; compensation cost for certain share-based performance awards and cash bonus assumptions. We consolidate the results of operations and financial position of a trade accounts receivable securitization which we consider a Variable Interest Entity (“VIE”) because we are the primary beneficiary, and we have the power to direct activities that most significantly affect the economic performance and have majority of the losses or benefits. collateral to the related debt. July 1, 2023 and December 31, 2022, certain trade accounts receivable that this VIE were $ 78 327 recourse to us were $ 60 255

Critical Accounting Policies an

Critical Accounting Policies and Recently Issued Accounting Standards	6 Months Ended
	Jul. 01, 2023
Critical Accounting Policies and Recently Issued Accounting Standards [Abstract]
Critical Accounting Policies and Recently Issued Accounting Standards	Note 2 – Critical Accounting Policies and Recently Issued Accounting Critical Accounting Policies There have been no material changes in our critical accounting policies as compared to the critical accounting policies described in Item 7 of our Annual ended December 31, 2022. Recently Issued Accounting Standards In September 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2022-04, “Liabilities – Supplier Finance Programs (Subtopic Program Obligations,” which will increase transparency of supplier finance such programs in connection with the purchase of goods and services to disclose information about such programs. including interim periods within those fiscal years, except for amended for fiscal years beginning after December 15, 2023. have a material impact on our condensed consolidated financial statements. In December 2022, the FASB issued ASU No. 2022-06, “Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848,” which extends the period of application of temporary optional expedients from December 21, 2022 to December 31, 2024. material impact on our condensed consolidated financial statements.

Net Sales from Contracts with C

Net Sales from Contracts with Customers	6 Months Ended
	Jul. 01, 2023
Net Sales from Contracts with Customers [Abstract]
Net sales from Contracts with Customers	Note 3 – Net Sales from Contracts with Customers Net sales are recognized in accordance with policies disclosed in Item the year ended December 31, 2022. Disaggregation of Net Sales The following table disaggregates our net sales by reportable segment and geographic Three Months Ended Six Months Ended July 1, 2023 July 1, 2023 North America International Global North America International Global Net sales: Health care distribution Dental $ 1,169 $ 788 $ 1,957 $ 2,313 $ 1,542 $ 3,855 Medical 925 25 950 1,876 45 1,921 Total health care distribution 2,094 813 2,907 4,189 1,587 5,776 Technology 168 25 193 334 50 384 Total net sales $ 2,262 $ 838 $ 3,100 $ 4,523 $ 1,637 $ 6,160 Three Months Ended Six Months Ended June 25, 2022 June 25, 2022 North America International Global North America International Global Net sales: Health care distribution Dental $ 1,124 $ 729 $ 1,853 $ 2,229 $ 1,452 $ 3,681 Medical 977 19 996 2,127 41 2,168 Total health care distribution 2,101 748 2,849 4,356 1,493 5,849 Technology 158 23 181 314 46 360 Total net sales $ 2,259 $ 771 $ 3,030 $ 4,670 $ 1,539 $ 6,209 Deferred Revenue During the six months ended July 1, 2023, we recognized in net sales $ 56 previously deferred at December 31, 2022. 86 million was reported in accrued expenses: other, and $ 8 reported in other liabilities. 86 million and $ 9

Segment Data

Segment Data	6 Months Ended
	Jul. 01, 2023
Segment Data [Abstract]
Segment Data	Note 4 Segment Data We conduct our business through two value-added services. dental businesses serve office-based dental practitioners, dental laboratories, schools, government institutions. medical technicians, dialysis centers, home health, federal and state governments group practices and integrated delivery networks, among other providers dental and medical groups serve practitioners in 33 The health care distribution reportable segment aggregates our global dental segment distributes consumable products, dental specialty products, small equipment, equipment repair services, branded and generic pharmaceuticals, tests, infection-control products, personal protective equipment (“PPE”) Our global technology and value-added services reportable segment provides added services to health care practitioners. systems for dental and medical practitioners. education, revenue cycle management and financial services on a non-recourse technology, network and hardware services, as well as continuing education services for practitioners. The following tables present information about our reportable and operating Three Months Ended Six Months Ended July 1, June 25, July 1, June 25, 2023 2022 2023 2022 Net Sales: Health care distribution (1) Dental $ 1,957 $ 1,853 $ 3,855 $ 3,681 Medical 950 996 1,921 2,168 Total health care distribution 2,907 2,849 5,776 5,849 Technology (2) 193 181 384 360 Total $ 3,100 $ 3,030 $ 6,160 $ 6,209 Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, dental specialty products (including implant, orthodontic and endodontic products), diagnostic tests, infection-control products, PPE products and vitamins. (2) Consists of practice management software and other value-added products, which are distributed primarily to health care providers, practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services. Three Months Ended Six Months Ended July 1, June 25, July 1, June 25, 2023 2022 2023 2022 Operating Income: Health care distribution $ 166 $ 189 $ 311 $ 400 Technology 35 31 65 64 Total $ 201 $ 220 $ 376 $ 464

Business Acquisitions

Business Acquisitions	6 Months Ended
	Jul. 01, 2023
Business Acquisitions [Abstract]
Business Acquisitions	Note 5 Business Acquisitions Our acquisition strategy is focused on investments in companies that our geographic footprint (whether entering a new country, such as emerging markets, or building scale where we have already invested in businesses), and finally, those that enable us to access new products and technologies. connection with our business acquisitions, the major classes of assets acquisition consideration to, excluding goodwill, include identifiable and lists, trademarks and trade names, product development and receivable. derived from analysis of market conditions, including discount rates, projected based on historical trends and assessment of financial projections), estimated flows. While we use our best estimates and assumptions to accurately value acquisition date as well as contingent consideration, where applicable, our subject to refinement. we may record adjustments to the assets acquired and liabilities assumed within our condensed consolidated balance sheets. the values of such assets acquired or liabilities assumed, whichever recognized in our condensed consolidated statements of operations. The accounting for certain of our acquisitions during the year ended December several areas, including but not limited to pending assessments of intangible assets and liabilities. recorded in our condensed consolidated statements of income relating to acquired, liabilities assumed and contingent consideration assets and liabilities. Acquisition of Biotech Dental On April 5, 2023, we acquired a 57 % voting equity interest in Biotech Dental (“Biotech Dental”), which provider of dental implants, clear aligners, and innovative digital dental has several important solutions, including Nemotec, a comprehensive, software using open architecture that connects disparate medical devices offering greater diagnostic accuracy and an improved patient experience. software with Henry Schein One’s industry-leading practice management software solutions will help customers streamline their clinical as well as administrative workflow for the ultimate The following table aggregates paid and net assets acquired in the Biotech Dental acquisition: 2023 Acquisition consideration: Cash $ 216 Fair value of contributed equity share in a controlled subsidiary 25 Redeemable noncontrolling interests 182 Total consideration $ 423 Identifiable assets acquired and liabilities assumed: Current assets $ 78 Intangible assets 119 Other noncurrent assets 76 Current liabilities (50) Long-term debt (90) Deferred income taxes (38) Other noncurrent liabilities (16) Total identifiable 79 Goodwill 344 Total net assets acquired $ 423 Goodwill is a result of expected synergies that are expected to originate from the growth potential of Biotech Dental. The accounting for the acquisition of Biotech Dental has limited to pending assessments of accounts receivable, inventory, intangible assets, right-of-use lease assets, accrued liabilities and income and non-income based taxes. valuation specialists to prepare appraisals. We will finalize the amounts recognized as the information necessary complete the analysis is obtained. We expect to finalize these amounts as soon as possible but no later than one year from the acquisition date. The pro forma financial information has not been presented because the during the three and six months ended July 1, 2023 was immaterial to our condensed statements. Other 2023 Acquisitions During the six months ended July 1, 2023, we acquired companies within and medical distribution segments. 51 % to 100 %. The following table aggregates paid and net assets acquired for these acquisitions during the six months 2023 Acquisition consideration: Cash $ 68 Deferred consideration 4 Estimated fair value of contingent consideration payable 3 Fair value of previously held equity method investment 29 Redeemable noncontrolling interests 31 Total consideration $ 135 Identifiable assets acquired and liabilities assumed: Current assets $ 21 Intangible assets 58 Other noncurrent assets 7 Current liabilities (11) Deferred income taxes (9) Other noncurrent liabilities (10) Total identifiable 56 Goodwill 79 Total net assets acquired $ 135 Goodwill is a result of the expected synergies and cross-selling opportunities that provide for us, as well as the expected growth potential. for tax purposes. In connection with an acquisition of a controlling interest of our affiliate, we recognized $ 18 cash flow model based on Level 3 inputs, as defined in The following table summarizes the preliminary identifiable intangible assets July 1, 2023 and their estimated useful lives as of the date of the acquisition: 2023 Estimated Useful Lives (in years) Customer relationships and lists $ 33 2 - 12 Trademarks/ Tradenames 6 5 - 10 Non-compete agreements 2 5 Product development 7 7 Patents 1 10 Other 9 5 Total $ 58 The pro forma financial information has not been presented because the and six months ended July 1, 2023 was immaterial to our condensed consolidated Acquisition Costs During the six months ended July 1, 2023 and June 25, 2022 we 13 3 in acquisition costs.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jul. 01, 2023
Fair Value Measurements [Abstract]
Fair Value Measurements	Note 6 – Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid transaction between market participants at the measurement date. (1) market participant assumptions developed based on market data obtained inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest in active markets for identical assets or liabilities (Level 1) and the lowest priority The three levels of the fair value hierarchy are described as follows: • measurement date. • either directly or indirectly. quoted prices for identical or similar assets or liabilities in markets prices that are observable for the asset or liability; and inputs that are derived observable market data by correlation or other means. • The following section describes the fair values of our financial instruments measure their fair values. Investments and notes receivable There are no quoted market prices available for investments in unconsolidated Certain of our notes receivable contain variable interest rates. estimate of fair value based on the interest rates in the applicable Debt The fair value of our debt (including bank credit lines, current maturities classified as Level 3 within the fair value hierarchy, and as of July 1, 2023 and December 31, 2022 was estimated at $ 1,524 1,149 debt include market conditions, such as interest rates and credit spreads. Derivative contracts Derivative contracts are valued using quoted market prices and derivative instruments to minimize our exposure to fluctuations in foreign instruments primarily include foreign currency forward agreements related forecasted inventory purchase commitments with foreign suppliers, portion of our euro-denominated foreign operations which are designated return swap for the purpose of economically hedging our unfunded plan and our deferred compensation plan. The fair values for the majority of our foreign currency derivative contracts are rate to a published forward price of the underlying market rates, which transactions and are classified within Level 2 of the fair value hierarchy. Total The fair value for the total return swap is measured by valuing using market-on-close pricing by industry providers as of the valuation fair value hierarchy. Redeemable noncontrolling interests The values for redeemable noncontrolling interests are classified within based on recent transactions and/or implied multiples of earnings. The following table presents our assets and liabilities that are measured and basis classified under the appropriate level of the fair value hierarchy as of July 1, 2023 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 21 $ - $ 21 Derivative contracts undesignated - 4 - 4 Total return - 3 - 3 Total assets $ - $ 28 $ - $ 28 Liabilities: Derivative contracts designated as hedges $ - $ 3 $ - $ 3 Derivative contracts undesignated - 3 - 3 Total liabilities $ - $ 6 $ - $ 6 Redeemable noncontrolling interests $ - $ - $ 820 $ 820 December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 23 $ - $ 23 Derivative contracts undesignated - 4 - 4 Total assets $ - $ 27 $ - $ 27 Liabilities: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 3 - 3 Total return - 3 - 3 Total liabilities $ - $ 7 $ - $ 7 Redeemable noncontrolling interests $ - $ - $ 576 $ 576

Debt

Debt	6 Months Ended
	Jul. 01, 2023
Debt [Abstract]
Debt	Note 7 – Debt Bank Credit Lines Bank credit lines consisted of the following: July 1, December 31, 2023 2022 Revolving credit agreement $ 250 $ - Other short-term bank credit lines 75 103 Total $ 325 $ 103 Revolving Credit Agreement On August 20, 2021 , we entered into a $ 1.0 which matures on August 20, 2026 . plus a spread based on our leverage ratio at the end of each financial rate on borrowings under this revolving credit agreement was 5.25 % plus 0.80 %, for a combined rate of 6.05 %. The Revolving Credit Agreement requires, among other things, that we Additionally, the Revolving Credit Agreement contains customary representations, warranties and affirmative covenants as well as customary negative covenants, subject to negotiated significant corporate changes (including mergers), dispositions and certain restrictive 2023 and December 31, 2022, we had $ 250 0 credit facility. 9 9 respectively, provided to third parties under this credit facility. On July 11, 2023, we amended and restated the Revolving Credit Agreement to, among other maturity date to July 11, 2028 and update the interest rate provisions to reflect the current market multicurrency facility. Financing Rate (“Term SOFR”) plus a spread based on our leverage ratio at the end of each financial reporting quarter (effective June 30, 2023). Other Short-Term Bank Credit As of July 1, 2023 and December 31, 2022, we had various other short-term currencies, with a maximum borrowing capacity of $ 426 402 and December 31, 2022, $ 75 103 December 31, 2022, borrowings under all of these credit lines had a weighted 12.09 % and 10.11 %, respectively. Long-term debt Long-term debt consisted of the following: July 1, December 31, 2023 2022 Private placement facilities $ 1,074 $ 699 U.S. trade accounts receivable securitization 60 330 Various in varying installments through 2023 at interest rates ranging from 0.00 % to 9.42 % at July 1, 2023 and ranging from 0.00 % to 3.50 % at December 31, 2022 49 7 Finance lease obligations 16 10 Total 1,199 1,046 Less current maturities (66) (6) Total long-term debt $ 1,133 $ 1,040 Private Placement Facilities Our private placement facilities include four 1.5 are available on an uncommitted basis at fixed rate economic time to time through October 20, 2026 . fixed rate based on an agreed upon spread over applicable treasury notes possible issuance will be selected by us and can range from five 15 years 12 years ). working capital and capital expenditures, to refinance existing indebtedness, The agreements provide, among other things, that we maintain restrictions relating to subsidiary indebtedness, liens, affiliate transactions, disposal ownership. applicable due dates. The components of our private placement facility borrowings, which 3.65 %, as of July 1, 2023 are presented in the following table: Amount of Borrowing Borrowing Date of Borrowing Outstanding Rate Due Date January 20, 2012 $ 50 3.45 % January 20, 2024 December 24, 2012 50 3.00 December 24, 2024 June 16, 2017 100 3.42 June 16, 2027 September 15, 2017 100 3.52 September 15, 2029 January 2, 2018 100 3.32 January 2, 2028 September 2, 2020 100 2.35 September 2, 2030 June 2, 2021 100 2.48 June 2, 2031 June 2, 2021 100 2.58 June 2, 2033 May 4, 2023 75 4.79 May 4, 2028 May 4, 2023 75 4.84 May 4, 2030 May 4, 2023 75 4.96 May 4, 2033 May 4, 2023 150 4.94 May 4, 2033 Less: Deferred debt issuance costs (1) Total $ 1,074 U.S. Trade Accounts Receivable Securitization We have a facility agreement based on the securitization of our U.S. trade accounts receivable that is structured as an asset-backed securitization program with pricing committed for up three years . purchase limit of $ 450 two December 15, 2025 . As of July 1, 2023 and December 31, 2022, the borrowings outstanding 60 million and $ 330 based on the asset-backed commercial paper rate of 5.38 % plus 0.75 %, for a combined rate of 6.13 %. December 31, 2022, the interest rate on borrowings under this facility was paper rate of 4.58 % plus 0.75 %, for a combined rate of 5.33 %. If our accounts receivable collection pattern changes due to customers our ability to borrow under this facility may be reduced. We are required to pay a commitment fee of 30 35 Term Loan On July 11, 2023, we entered into a three -year $ 750 Agreement”). ratio at the end of each financial reporting quarter. new credit facility for working capital and general corporate purposes, expenditures, the repurchase of the Company’s capital stock and permitted refinancing of existing debt, as well as for funding potential acquisitions. certain maximum leverage ratios. warranties and affirmative covenants as well as customary negative covenants, subject liens, indebtedness, significant corporate changes (including mergers), dispositions agreements.

Income Taxes

Income Taxes	6 Months Ended
	Jul. 01, 2023
Income Taxes [Abstract]
Income Taxes	Note 8 – Income Taxes For the six months ended July 1, 2023 our effective tax rate was 22.8 %, compared to 23.9 % for the prior year period. foreign income taxes and interest expense. The total amount of unrecognized tax benefits, which are included in consolidated balance sheets, as of July 1, 2023 and December 31, 2022 was 103 94 respectively, of which $ 88 80 It is possible that the amount of unrecognized tax benefits will change material impact on our condensed consolidated statements of income. All tax returns audited by the IRS are officially closed through 2019. IRS include years 2020 and forward. examination. The total amounts of interest and penalties are classified as a component amount of tax interest expense was $ 1 0 months ended June 25, 2022. 14 million as of July 1, 2023 and $ 12 the periods presented were not material to our condensed consolidated financial

Plan of Restructuring

Plan of Restructuring	6 Months Ended
	Jul. 01, 2023
Plan of Restructuring [Abstract]
Plan of Restructuring	Note 9 – Plan of Restructuring On August 1, 2022, we committed to a restructuring plan focused on streamlining operations and other initiatives to increase efficiency. completion and now expect this initiative to extend through 2024. determination of an estimate of the amount or range of amounts expected to activities, both with respect to each major type of cost associated estimate of the amount or range of amounts that will result in future During the three and six months ended July 1, 2023, we recorded restructuring 18 48 respectively. accelerated amortization of right-of-use lease assets and fixed assets, and other restructuring costs for the six months ended July 1, 2023 were unprofitable U.S. business initiated during 2022 and completed during Restructuring costs recorded for the three and six months ended July 1, no Three Months Ended July 1, 2023 Health-Care Distribution Technology Value-Added Services Total Severance and employee-related costs $ 13 $ 1 $ 14 Accelerated depreciation and amortization 2 1 3 Exit and other related costs 1 - 1 Total restructuring $ 16 $ 2 $ 18 Six Months Ended July 1, 2023 Health-Care Distribution Technology Value-Added Services Total Severance and employee-related costs $ 30 $ 4 $ 34 Accelerated depreciation and amortization 9 1 10 Exit and other related costs 2 1 3 Loss on disposal of a business 1 - 1 Total restructuring $ 42 $ 6 $ 48 The following table summarizes, restructuring initiatives of July 1, 2023 is included in accrued expenses: other within our condensed related to exited leased facilities are recorded within our current and non-current our condensed consolidated balance sheet. Technology Health Care Value-Added Distribution Services Total Balance, December 31, 2022 $ 21 $ 3 $ 24 Restructuring costs 42 6 48 Non-cash asset impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets (9) (1) (10) Cash payments and other adjustments (24) (5) (29) Balance, July 1, 2023 $ 30 $ 3 $ 33

Legal Proceedings

Legal Proceedings	6 Months Ended
	Jul. 01, 2023
Legal Proceedings [Abstract]
Legal Proceedings	Note 10 – Legal Proceedings Henry Schein, Inc. has been named as a defendant in multiple opioid hundred and seventy-five ( 175 ); one or more of Henry Schein, Inc.’s subsidiaries is also named as a defendant in a number of those cases). in a false advertising campaign to expand the market for such drugs and their in the supply chain (including Henry Schein, Inc. and its affiliated companies) reaped or otherwise failing to monitor appropriately and restrict the improper consist of some that have been consolidated within the MultiDistrict Litigation Prescription Opiate Litigation (MDL No. 2804; Case No. 17-md-2804) remain pending in state courts and are proceeding independently and outside following cases are set for trial: the action filed by Mobile County Board which has been set for a jury trial on August 12, 2024; and the action filed (and 38 for a jury trial in May 2025. 12.6 operations, sales of opioids represented less than two-tenths business. In August 2022, Henry Schein received a Grand Jury Subpoena from the United Western District of Virginia, Federal Food, Drug & Cosmetic Act by Butler Animal Health Supply, LLC (“Butler”), a former subsidiary of Henry Schein. October 2022, Henry Schein received a second Grand Jury Subpoena from the Western District of Virginia. received from Butler or Covetrus, Inc. (“Covetrus”). subsidiary of Covetrus in 2019 and is no longer owned by Henry Schein. investigation. From time to time, we may become a party to other legal proceedings, liability claims, employment matters, commercial disputes, governmental in some cases involve our entering into settlement arrangements or consent of the ordinary course of our business. in our opinion none of these other pending matters are currently consolidated financial position, liquidity or results of operations. As of July 1, 2023, we had accrued our best estimate of potential losses relating result in liability and for which we were able to reasonably estimate a expenses, was not material to our financial position, results of operations determining estimated losses considers currently available factors, including probable recoveries from third parties.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jul. 01, 2023
Stock-Based Compensation [Abstract]
Stock-Based Compensation	Note 11 – Stock-Based Compensation Stock-based awards are provided to certain employees under the terms of non-employee directors under the terms of our 2015 Non-Employee Director “Plans”). “Compensation Committee”). form of time-based and performance-based restricted stock units (“RSUs”) in which non-qualified stock options were issued in place of performance-based based and performance-based RSUs, as well as non-qualified stock granting our employees equity-based awards solely in the form of time-based non-employee directors receive equity-based awards solely in the form RSUs are stock-based awards granted to recipients with specified vesting provisions. stock is delivered on or following satisfaction of vesting conditions. vest (i) solely based on the recipient’s continued service over time, primarily with four -year cliff vesting and/or (ii) based on achieving specified performance measurements and the recipient’s continued service over time, primarily with three -year cliff vesting. 12 -month cliff vesting. With respect to time-based RSUs, we estimate the fair value based on our closing stock price on the date of grant. recipient is based upon our performance as measured against specified determined by the Compensation Committee. achieved, we estimate the fair value of performance-based RSUs based on Each of the Plans provide for certain adjustments to the performance the Plans. performance measurement adjustments relate to significant events, including, divestitures, new business ventures, certain capital transactions (including share budgeted average outstanding shares (other than those resulting from capital restructuring costs, if any, certain litigation settlements or payments, if any, changes in accounting principles or in applicable laws or regulations, changes in income tax rates in certain financial impact either positive or negative, of the difference in projected earnings (solely with respect to performance-based RSUs granted in the 2022 and (solely with respect to performance-based RSUs granted in the 2023 plan circumstances affecting us. Over the performance period, the number of shares of common stock that will related compensation expense is adjusted upward or downward based upon performance targets. recognized as an expense will be based on our actual performance metrics as Stock options are awards that allow the recipient to purchase shares of our vesting of the stock options. date of grant. one-third service, subject to the terms and conditions of the 2020 Stock Incentive Plan, three years grant date and have a contractual term of ten years upon certain events. We estimated the fair value of stock options using the Black-Scholes valuation model. ended July 1, 2023 we did no t grant any stock options. Our accompanying condensed consolidated statements of income reflect of $ 14 11 24 19 July 1, 2023, respectively. compensation expense of $ 15 12 27 21 Total unrecognized compensation cost related to unvested awards as of July 1, 2023 was $ 107 expected to be recognized over a weighted-average period of approximately 2.4 Our accompanying condensed consolidated statements of cash flows present as an adjustment to reconcile net income to net cash provided by operating the accompanying consolidated statements of cash flows, there were no excess of recognized compensation as a cash inflow from financing and June 25, 2022, respectively. We have not declared cash dividends on our stock in the past and we do not anticipate declaring cash dividends in the foreseeable future. our stock, historical volatility of our stock, and other factors. Treasury yield curve in effect at the time of grant in conjunction with considering the expected life of options. six -year expected life of the options was determined using the simplified as permitted under SAB Topic 14. value ultimately realized by recipients of stock options, and subsequent events reasonableness of the original estimates of fair value made by us. The following table summarizes the stock option activity during the six months Stock Options Weighted Average Weighted Average Aggregate Exercise Remaining Contractual Shares Price Life (in years) Outstanding at beginning of period 1,117,574 $ 71.38 Exercised (17,905) 62.71 Forfeited (7,541) 78.22 Outstanding at end of period 1,092,128 $ 71.48 8.1 $ 12 Options exercisable at end of period 568,623 $ 68.25 Weighted Average Weighted Average Aggregate Number of Exercise Remaining Contractual Intrinsic Options Price Life (in years) Value Vested 517,576 $ 75.12 8.3 $ 4 The following tables summarize the activity of our unvested RSUs for Time-Based Restricted Stock Units Performance-Based Restricted Stock Units Weighted Average Weighted Average Grant Date Fair Intrinsic Value Grant Date Fair Intrinsic Value Shares/Units Value Per Share Per Share Shares/Units Value Per Share Per Share Outstanding at beginning of period 1,756,044 $ 66.59 520,916 $ 60.23 Granted 407,570 77.70 530,224 78.38 Vested (406,604) 61.66 (630,294) 60.64 Forfeited (54,420) 71.07 (49,524) 76.09 Outstanding at end of period 1,702,590 $ 70.34 $ 81.10 371,322 $ 69.62 $ 81.10

Redeemable Noncontrolling Inter

Redeemable Noncontrolling Interests	6 Months Ended
	Jul. 01, 2023
Redeemable Noncontrolling Interests [Abstract]
Redeemable Noncontrolling Interests	Note 12 – Redeemable Noncontrolling Interests Some minority stockholders in certain of our subsidiaries have the right, their ownership interest in those entities at fair value. applicable for noncontrolling interests where we are or may be required outstanding interest in a consolidated subsidiary from the noncontrolling option contained in contractual agreements. interests for the six months ended July 1, 2023 and the year ended December following table: July 1, December 31, 2023 2022 Balance, beginning of period $ 576 $ 613 Decrease in redeemable noncontrolling interests due to acquisitions of noncontrolling interests in subsidiaries (13) (31) Increase in redeemable noncontrolling interests due to business acquisitions 240 4 Net income attributable to redeemable noncontrolling interests 9 21 Dividends declared (7) (21) Effect of foreign currency translation gain (loss) attributable to redeemable noncontrolling interests 1 (6) Change in fair value of redeemable securities 14 (4) Balance, end of period $ 820 $ 576

Comprehensive Income

Comprehensive Income	6 Months Ended
	Jul. 01, 2023
Comprehensive Income [Abstract]
Comprehensive Income	Note 13 – Comprehensive Income Comprehensive income includes certain gains and losses that, under U.S. such amounts are recorded directly as an adjustment to stockholders’ The following table summarizes our Accumulated other comprehensive loss, net of July 1, December 31, 2023 2022 Attributable to redeemable noncontrolling interests: Foreign currency translation adjustment $ (36) $ (37) Attributable to noncontrolling interests: Foreign currency translation adjustment $ (1) $ (1) Attributable to Henry Schein, Inc.: Foreign currency translation adjustment $ (209) $ (236) Unrealized gain from foreign currency hedging activities 1 5 Pension adjustment loss (2) (2) Accumulated other comprehensive loss $ (210) $ (233) Total Accumulated $ (247) $ (271) The following table summarizes the components of comprehensive income, net Three Months Ended Six Months Ended July 1, June 25, July 1, June 25, 2023 2022 2023 2022 Net income $ 148 $ 167 $ 276 $ 353 Foreign currency translation gain (loss) 3 (90) 28 (87) Tax effect - - - - Foreign currency translation gain (loss) 3 (90) 28 (87) Unrealized gain (loss) from foreign currency hedging (2) 10 (6) 12 Tax effect 1 (2) 2 (3) Unrealized gain (loss) from foreign currency hedging (1) 8 (4) 9 Comprehensive income $ 150 $ 85 $ 300 $ 275 Our financial statements are denominated in the U.S. Dollar currency. currencies as compared to the U.S. Dollar may have a significant impact foreign currency translation gain (loss) during the six months ended 2022 was primarily due to changes in foreign currency exchange rates of Canadian Dollar, Euro, Australian Dollar, Chinese Yuan, The following table summarizes our total comprehensive income, net of Three Months Ended Six Months Ended July 1, June 25, July 1, June 25, 2023 2022 2023 2022 Comprehensive income attributable to Henry Schein, Inc. $ 143 $ 87 $ 284 $ 271 Comprehensive income attributable to noncontrolling interests 3 1 6 2 Comprehensive income (loss) attributable to redeemable noncontrolling interests 4 (3) 10 2 Comprehensive income $ 150 $ 85 $ 300 $ 275

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jul. 01, 2023
Earnings Per Share [Abstract]
Earnings Per Share	Note 14 Earnings Per Share Basic earnings per share is computed by dividing net income attributable average number of common shares outstanding for the period. to basic earnings per share, except that it reflects the effect of common shares issuable and upon exercise of stock options using the treasury stock method A reconciliation of shares used in calculating earnings per basic and Three Months Ended Six Months Ended July 1, June 25, July 1, June 25, 2023 2022 2023 2022 Basic 130,905,899 137,350,488 131,136,450 137,323,076 Effect of dilutive securities: Stock options and restricted stock units 967,275 1,518,576 1,329,299 1,732,129 Diluted 131,873,174 138,869,064 132,465,749 139,055,205 The number of antidilutive securities that were excluded from the calculation shares outstanding are as follows: Three Months Ended Six Months Ended July 1, June 25, July 1, June 25, 2023 2022 2023 2022 Stock options 426,002 423,786 427,355 250,226 Restricted stock units 19,405 51,453 19,405 226,203 Total anti-dilutive computation 445,407 475,239 446,760 476,429

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	6 Months Ended
	Jul. 01, 2023
Supplemental Cash Flow information [Abstract]
Supplemental Cash Flow Information	Note 15 – Supplemental Cash Flow Information Cash paid for interest and income taxes was: Six Months Ended July 1, June 25, 2023 2022 Interest $ 32 $ 17 Income taxes 118 165 During the six months ended July 1, 2023 and June 25, 2022, we had (6) 12 unrealized gains (losses) related to foreign currency hedging activities, respectively.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jul. 01, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 16 – Related Party Transactions In connection with the formation of Henry Schein One, LLC, our joint venture formed on July 1, 2018, we entered into a ten-year Internet Brands approximately $ 31 six months ended July 1, 2023, we recorded $ 8 16 related to this royalty agreement. 8 and $ 16 December 31, 2022, Henry Schein One, LLC had a net payable balance due 10 $ 9 components of this payable are recorded within accrued expenses: other, within our condensed consolidated balance sheets. 27 Internet Brands, which was paid subsequent to July 1, 2023. During our normal course of business, we have interests in entities that we account for under the equity accounting method. 11 23 respectively, to such entities. 11 million and $ 23 purchased $ 3 5 25, 2022, we purchased $ 3 6 31, 2022, we had an aggregate of $ 33 36 5 million and $ 6 Certain of our facilities related to our acquisitions are leased from employees leases are classified as operating leases and have a remaining lease term one year 14 years. 6 million and $ 25 7.6 % and 9.0 % of the total current and non- current operating lease liabilities.

Critical Accounting Policies _2

Critical Accounting Policies and Recently Issued Accounting Standards (Policy)	6 Months Ended
	Jul. 01, 2023
Critical Accounting Policies and Recently Issued Accounting Standards [Abstract]
Accounting Pronouncements Adopted and Recently Issued Accounting Standards	Recently Issued Accounting Standards In September 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2022-04, “Liabilities – Supplier Finance Programs (Subtopic Program Obligations,” which will increase transparency of supplier finance such programs in connection with the purchase of goods and services to disclose information about such programs. including interim periods within those fiscal years, except for amended for fiscal years beginning after December 15, 2023. have a material impact on our condensed consolidated financial statements. In December 2022, the FASB issued ASU No. 2022-06, “Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848,” which extends the period of application of temporary optional expedients from December 21, 2022 to December 31, 2024. material impact on our condensed consolidated financial statements.

Net Sales from Contracts with_2

Net Sales from Contracts with Customers (Tables)	6 Months Ended
	Jul. 01, 2023
Net Sales from Contracts with Customers [Abstract]
Disaggregation of Revenue	Three Months Ended Six Months Ended July 1, 2023 July 1, 2023 North America International Global North America International Global Net sales: Health care distribution Dental $ 1,169 $ 788 $ 1,957 $ 2,313 $ 1,542 $ 3,855 Medical 925 25 950 1,876 45 1,921 Total health care distribution 2,094 813 2,907 4,189 1,587 5,776 Technology 168 25 193 334 50 384 Total net sales $ 2,262 $ 838 $ 3,100 $ 4,523 $ 1,637 $ 6,160 Three Months Ended Six Months Ended June 25, 2022 June 25, 2022 North America International Global North America International Global Net sales: Health care distribution Dental $ 1,124 $ 729 $ 1,853 $ 2,229 $ 1,452 $ 3,681 Medical 977 19 996 2,127 41 2,168 Total health care distribution 2,101 748 2,849 4,356 1,493 5,849 Technology 158 23 181 314 46 360 Total net sales $ 2,259 $ 771 $ 3,030 $ 4,670 $ 1,539 $ 6,209

Segment Data (Tables)

Segment Data (Tables)	6 Months Ended
	Jul. 01, 2023
Segment Data [Abstract]
Business segment information	Three Months Ended Six Months Ended July 1, June 25, July 1, June 25, 2023 2022 2023 2022 Net Sales: Health care distribution (1) Dental $ 1,957 $ 1,853 $ 3,855 $ 3,681 Medical 950 996 1,921 2,168 Total health care distribution 2,907 2,849 5,776 5,849 Technology (2) 193 181 384 360 Total $ 3,100 $ 3,030 $ 6,160 $ 6,209 Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, dental specialty products (including implant, orthodontic and endodontic products), diagnostic tests, infection-control products, PPE products and vitamins. (2) Consists of practice management software and other value-added products, which are distributed primarily to health care providers, practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services. Three Months Ended Six Months Ended July 1, June 25, July 1, June 25, 2023 2022 2023 2022 Operating Income: Health care distribution $ 166 $ 189 $ 311 $ 400 Technology 35 31 65 64 Total $ 201 $ 220 $ 376 $ 464

Business Acquisitions (Tables)

Business Acquisitions (Tables)	6 Months Ended
	Jul. 01, 2023
Biotech Dental [Member]
Business Acquisition [Line Items]
Summary of Estimated Fair Value of Consideration Paid and Net Assets Acquired	2023 Acquisition consideration: Cash $ 216 Fair value of contributed equity share in a controlled subsidiary 25 Redeemable noncontrolling interests 182 Total consideration $ 423 Identifiable assets acquired and liabilities assumed: Current assets $ 78 Intangible assets 119 Other noncurrent assets 76 Current liabilities (50) Long-term debt (90) Deferred income taxes (38) Other noncurrent liabilities (16) Total identifiable 79 Goodwill 344 Total net assets acquired $ 423
Series Of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Summary of Estimated Fair Value of Consideration Paid and Net Assets Acquired	2023 Acquisition consideration: Cash $ 68 Deferred consideration 4 Estimated fair value of contingent consideration payable 3 Fair value of previously held equity method investment 29 Redeemable noncontrolling interests 31 Total consideration $ 135 Identifiable assets acquired and liabilities assumed: Current assets $ 21 Intangible assets 58 Other noncurrent assets 7 Current liabilities (11) Deferred income taxes (9) Other noncurrent liabilities (10) Total identifiable 56 Goodwill 79 Total net assets acquired $ 135
Summary of Identifiable Intangible Assets Acquired and Estimated Useful Lives	2023 Estimated Useful Lives (in years) Customer relationships and lists $ 33 2 - 12 Trademarks/ Tradenames 6 5 - 10 Non-compete agreements 2 5 Product development 7 7 Patents 1 10 Other 9 5 Total $ 58

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jul. 01, 2023
Fair Value Measurements [Abstract]
Fair value - assets and liabilities measured and recognized on a recurring basis	July 1, 2023 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 21 $ - $ 21 Derivative contracts undesignated - 4 - 4 Total return - 3 - 3 Total assets $ - $ 28 $ - $ 28 Liabilities: Derivative contracts designated as hedges $ - $ 3 $ - $ 3 Derivative contracts undesignated - 3 - 3 Total liabilities $ - $ 6 $ - $ 6 Redeemable noncontrolling interests $ - $ - $ 820 $ 820 December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 23 $ - $ 23 Derivative contracts undesignated - 4 - 4 Total assets $ - $ 27 $ - $ 27 Liabilities: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 3 - 3 Total return - 3 - 3 Total liabilities $ - $ 7 $ - $ 7 Redeemable noncontrolling interests $ - $ - $ 576 $ 576

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jul. 01, 2023
Debt [Abstract]
Schedule of Bank Credit Lines	July 1, December 31, 2023 2022 Revolving credit agreement $ 250 $ - Other short-term bank credit lines 75 103 Total $ 325 $ 103
Schedule of Long-Term Debt	July 1, December 31, 2023 2022 Private placement facilities $ 1,074 $ 699 U.S. trade accounts receivable securitization 60 330 Various in varying installments through 2023 at interest rates ranging from 0.00 % to 9.42 % at July 1, 2023 and ranging from 0.00 % to 3.50 % at December 31, 2022 49 7 Finance lease obligations 16 10 Total 1,199 1,046 Less current maturities (66) (6) Total long-term debt $ 1,133 $ 1,040
Schedule of Private Placement Facility Borrowings	Amount of Borrowing Borrowing Date of Borrowing Outstanding Rate Due Date January 20, 2012 $ 50 3.45 % January 20, 2024 December 24, 2012 50 3.00 December 24, 2024 June 16, 2017 100 3.42 June 16, 2027 September 15, 2017 100 3.52 September 15, 2029 January 2, 2018 100 3.32 January 2, 2028 September 2, 2020 100 2.35 September 2, 2030 June 2, 2021 100 2.48 June 2, 2031 June 2, 2021 100 2.58 June 2, 2033 May 4, 2023 75 4.79 May 4, 2028 May 4, 2023 75 4.84 May 4, 2030 May 4, 2023 75 4.96 May 4, 2033 May 4, 2023 150 4.94 May 4, 2033 Less: Deferred debt issuance costs (1) Total $ 1,074

Plan of Restructuring (Tables)

Plan of Restructuring (Tables)	6 Months Ended
	Jul. 01, 2023
Plan of Restructuring [Abstract]
Schedule of Restructuring Costs	Three Months Ended July 1, 2023 Health-Care Distribution Technology Value-Added Services Total Severance and employee-related costs $ 13 $ 1 $ 14 Accelerated depreciation and amortization 2 1 3 Exit and other related costs 1 - 1 Total restructuring $ 16 $ 2 $ 18 Six Months Ended July 1, 2023 Health-Care Distribution Technology Value-Added Services Total Severance and employee-related costs $ 30 $ 4 $ 34 Accelerated depreciation and amortization 9 1 10 Exit and other related costs 2 1 3 Loss on disposal of a business 1 - 1 Total restructuring $ 42 $ 6 $ 48
Schedule of Restructuring Reserve by Segment	Technology Health Care Value-Added Distribution Services Total Balance, December 31, 2022 $ 21 $ 3 $ 24 Restructuring costs 42 6 48 Non-cash asset impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets (9) (1) (10) Cash payments and other adjustments (24) (5) (29) Balance, July 1, 2023 $ 30 $ 3 $ 33

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jul. 01, 2023
Stock-Based Compensation [Abstract]
Summary of Stock Option Activity Under the Plans	Stock Options Weighted Average Weighted Average Aggregate Exercise Remaining Contractual Shares Price Life (in years) Outstanding at beginning of period 1,117,574 $ 71.38 Exercised (17,905) 62.71 Forfeited (7,541) 78.22 Outstanding at end of period 1,092,128 $ 71.48 8.1 $ 12 Options exercisable at end of period 568,623 $ 68.25
Intrinsic Values	Weighted Average Weighted Average Aggregate Number of Exercise Remaining Contractual Intrinsic Options Price Life (in years) Value Vested 517,576 $ 75.12 8.3 $ 4
Status of Unvested RSUs	Time-Based Restricted Stock Units Performance-Based Restricted Stock Units Weighted Average Weighted Average Grant Date Fair Intrinsic Value Grant Date Fair Intrinsic Value Shares/Units Value Per Share Per Share Shares/Units Value Per Share Per Share Outstanding at beginning of period 1,756,044 $ 66.59 520,916 $ 60.23 Granted 407,570 77.70 530,224 78.38 Vested (406,604) 61.66 (630,294) 60.64 Forfeited (54,420) 71.07 (49,524) 76.09 Outstanding at end of period 1,702,590 $ 70.34 $ 81.10 371,322 $ 69.62 $ 81.10

Redeemable Noncontrolling Int_2

Redeemable Noncontrolling Interests (Tables)	6 Months Ended
	Jul. 01, 2023
Redeemable Noncontrolling Interests [Abstract]
Components of the Change in Redeemable Noncontrolling Interests	July 1, December 31, 2023 2022 Balance, beginning of period $ 576 $ 613 Decrease in redeemable noncontrolling interests due to acquisitions of noncontrolling interests in subsidiaries (13) (31) Increase in redeemable noncontrolling interests due to business acquisitions 240 4 Net income attributable to redeemable noncontrolling interests 9 21 Dividends declared (7) (21) Effect of foreign currency translation gain (loss) attributable to redeemable noncontrolling interests 1 (6) Change in fair value of redeemable securities 14 (4) Balance, end of period $ 820 $ 576

Comprehensive Income (Tables)

Comprehensive Income (Tables)	6 Months Ended
	Jul. 01, 2023
Comprehensive Income [Abstract]
Accumulated Other Comprehensive Loss Net of Applicable Taxes	July 1, December 31, 2023 2022 Attributable to redeemable noncontrolling interests: Foreign currency translation adjustment $ (36) $ (37) Attributable to noncontrolling interests: Foreign currency translation adjustment $ (1) $ (1) Attributable to Henry Schein, Inc.: Foreign currency translation adjustment $ (209) $ (236) Unrealized gain from foreign currency hedging activities 1 5 Pension adjustment loss (2) (2) Accumulated other comprehensive loss $ (210) $ (233) Total Accumulated $ (247) $ (271)
Components of Comprehensive Income, Net of Applicable Taxes	Three Months Ended Six Months Ended July 1, June 25, July 1, June 25, 2023 2022 2023 2022 Net income $ 148 $ 167 $ 276 $ 353 Foreign currency translation gain (loss) 3 (90) 28 (87) Tax effect - - - - Foreign currency translation gain (loss) 3 (90) 28 (87) Unrealized gain (loss) from foreign currency hedging (2) 10 (6) 12 Tax effect 1 (2) 2 (3) Unrealized gain (loss) from foreign currency hedging (1) 8 (4) 9 Comprehensive income $ 150 $ 85 $ 300 $ 275
Total Comprehensive Income, Net of Applicable Taxes	Three Months Ended Six Months Ended July 1, June 25, July 1, June 25, 2023 2022 2023 2022 Comprehensive income attributable to Henry Schein, Inc. $ 143 $ 87 $ 284 $ 271 Comprehensive income attributable to noncontrolling interests 3 1 6 2 Comprehensive income (loss) attributable to redeemable noncontrolling interests 4 (3) 10 2 Comprehensive income $ 150 $ 85 $ 300 $ 275

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jul. 01, 2023
Earnings Per Share [Abstract]
Reconciliation of Shares used in Calculating Earnings per Share Basic and Diluted	Three Months Ended Six Months Ended July 1, June 25, July 1, June 25, 2023 2022 2023 2022 Basic 130,905,899 137,350,488 131,136,450 137,323,076 Effect of dilutive securities: Stock options and restricted stock units 967,275 1,518,576 1,329,299 1,732,129 Diluted 131,873,174 138,869,064 132,465,749 139,055,205
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Three Months Ended Six Months Ended July 1, June 25, July 1, June 25, 2023 2022 2023 2022 Stock options 426,002 423,786 427,355 250,226 Restricted stock units 19,405 51,453 19,405 226,203 Total anti-dilutive computation 445,407 475,239 446,760 476,429

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	6 Months Ended
	Jul. 01, 2023
Supplemental Cash Flow information [Abstract]
Cash paid for interest and income taxes	Six Months Ended July 1, June 25, 2023 2022 Interest $ 32 $ 17 Income taxes 118 165

Basis of Presentation - Narrati

Basis of Presentation - Narrative (Details) - Variable Interest Entity, Primary Beneficiary [Member] - USD ($) $ in Millions	Jul. 01, 2023	Dec. 31, 2022
Asset Pledged as Collateral [Member]
Pledged assets	$ 78	$ 327
Recourse [Member]
Liabilities of VIE	$ 60	$ 255

Net Sales from Contracts with_3

Net Sales from Contracts with Customers - Narrative (Details) - USD ($) $ in Millions	6 Months Ended
	Jul. 01, 2023	Dec. 31, 2022
Net Sales from Contracts with Customers [Abstract]
Contract with Customer, Liability, Current	$ 86	$ 86
Contract with Customer, Liability, Noncurrent	9	$ 8
Contract with Customer, Liability, Revenue Recognized	$ 56

Net Sales from Contracts with_4

Net Sales from Contracts with Customers - Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jun. 25, 2022	Jul. 01, 2023	Jun. 25, 2022
Disaggregation of Revenue [Abstract]
Net sales	$ 3,100	$ 3,030	$ 6,160	$ 6,209
North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	2,262	2,259	4,523	4,670
International [Member]
Disaggregation of Revenue [Abstract]
Net sales	838	771	1,637	1,539
Health Care Distribution [Member]
Disaggregation of Revenue [Abstract]
Net sales	2,907	2,849	5,776	5,849
Health Care Distribution [Member] | North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	2,094	2,101	4,189	4,356
Health Care Distribution [Member] | International [Member]
Disaggregation of Revenue [Abstract]
Net sales	813	748	1,587	1,493
Health Care Distribution [Member] | Dental [Member]
Disaggregation of Revenue [Abstract]
Net sales	1,957	1,853	3,855	3,681
Health Care Distribution [Member] | Dental [Member] | North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	1,169	1,124	2,313	2,229
Health Care Distribution [Member] | Dental [Member] | International [Member]
Disaggregation of Revenue [Abstract]
Net sales	788	729	1,542	1,452
Health Care Distribution [Member] | Medical [Member]
Disaggregation of Revenue [Abstract]
Net sales	950	996	1,921	2,168
Health Care Distribution [Member] | Medical [Member] | North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	925	977	1,876	2,127
Health Care Distribution [Member] | Medical [Member] | International [Member]
Disaggregation of Revenue [Abstract]
Net sales	25	19	45	41
Technology and Value-Added Services [Member]
Disaggregation of Revenue [Abstract]
Net sales	193	181	384	360
Technology and Value-Added Services [Member] | North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	168	158	334	314
Technology and Value-Added Services [Member] | International [Member]
Disaggregation of Revenue [Abstract]
Net sales	$ 25	$ 23	$ 50	$ 46

Segment Data (Details)

Segment Data (Details) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2023 USD ($) countries	Jun. 25, 2022 USD ($)	Jul. 01, 2023 USD ($) segments countries	Jun. 25, 2022 USD ($)
Segment Data [Abstract]
Number of reportable segments | segments			2
Segment Reporting Information [Line Items]
Net sales	$ 3,100	$ 3,030	$ 6,160	$ 6,209
Operating income	201	220	376	464
Health Care Distribution [Member]
Segment Reporting Information [Line Items]
Net sales	2,907	2,849	5,776	5,849
Operating income	$ 166	189	$ 311	400
Number of countries served globally | countries	33		33
Health Care Distribution [Member] | Dental [Member]
Segment Reporting Information [Line Items]
Net sales	$ 1,957	1,853	$ 3,855	3,681
Health Care Distribution [Member] | Medical [Member]
Segment Reporting Information [Line Items]
Net sales	950	996	1,921	2,168
Technology and Value-Added Services [Member]
Segment Reporting Information [Line Items]
Net sales	193	181	384	360
Operating income	$ 35	$ 31	$ 65	$ 64

Business Acquisitions - Narrati

Business Acquisitions - Narrative (Details) - USD ($) $ in Millions	6 Months Ended
	Jul. 01, 2023	Apr. 05, 2023	Jun. 25, 2022
Business Acquisition [Line Items]
Recognized gain related to remeasurement to fair value of previously held equity investment	$ 18
Acquisition costs	13		$ 3
Biotech Dental [Member]
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired		57%
Series Of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired	58
Series Of Individually Immaterial Business Acquisitions [Member] | Customer Relationships and Lists [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired	33
Series Of Individually Immaterial Business Acquisitions [Member] | Trademarks And Trade Names [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired	$ 6
Series Of Individually Immaterial Business Acquisitions [Member] | Minimum [Member]
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	51%
Series Of Individually Immaterial Business Acquisitions [Member] | Minimum [Member] | Customer Relationships and Lists [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)	2 years
Series Of Individually Immaterial Business Acquisitions [Member] | Minimum [Member] | Trademarks And Trade Names [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)	5 years
Series Of Individually Immaterial Business Acquisitions [Member] | Maximum [Member]
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	100%
Series Of Individually Immaterial Business Acquisitions [Member] | Maximum [Member] | Customer Relationships and Lists [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)	12 years
Series Of Individually Immaterial Business Acquisitions [Member] | Maximum [Member] | Trademarks And Trade Names [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)	10 years

Business Acquisitions - Summary

Business Acquisitions - Summary of Estimated Fair Value of Consideration Paid and Net Assets Acquired (Details) - USD ($) $ in Millions		6 Months Ended
	Apr. 05, 2023	Jul. 01, 2023	Dec. 31, 2022
Identifiable assets acquired and liabilities assumed:
Goodwill		$ 3,335	$ 2,893
Biotech Dental [Member]
Acquisition consideration:
Cash	$ 216
Fair value of contributed equity share in a controlled subsidiary	25
Redeemable noncontrolling interests	182
Total consideration	423
Identifiable assets acquired and liabilities assumed:
Current assets	78
Intangible assets	119
Other noncurrent assets	76
Current liabilities	(50)
Lomg-term debt	(90)
Deferred income taxes	(38)
Other noncurrent liabilities	(16)
Total identifiable net assets	79
Goodwill	344
Total net assets acquired	$ 423
Series Of Individually Immaterial Business Acquisitions [Member]
Acquisition consideration:
Cash		68
Deferred consideration		4
Other		3
Fair value of contributed equity share in a controlled subsidiary		29
Redeemable noncontrolling interests		31
Total consideration		135
Identifiable assets acquired and liabilities assumed:
Current assets		21
Intangible assets		58
Other noncurrent assets		7
Current liabilities		(11)
Deferred income taxes		(9)
Other noncurrent liabilities		(10)
Total identifiable net assets		56
Goodwill		79
Total net assets acquired		$ 135

Business Acquisitions - Summa_2

Business Acquisitions - Summary of Identifiable Intangible Assets Acquired and Estimated Useful Lives (Details) - Series Of Individually Immaterial Business Acquisitions [Member] $ in Millions	6 Months Ended
	Jul. 01, 2023 USD ($)
Business Acquisition [Line Items]
Identifiable intangible assets acquired	$ 58
Customer Relationships and Lists [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired	$ 33
Customer Relationships and Lists [Member] | Minimum [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)	2 years
Customer Relationships and Lists [Member] | Maximum [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)	12 years
Trademarks/Tradenames [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired	$ 6
Trademarks/Tradenames [Member] | Minimum [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)	5 years
Trademarks/Tradenames [Member] | Maximum [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)	10 years
Noncompete Agreements [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired	$ 2
Estimated useful lives (in years)	5 years
Product Development [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired	$ 7
Estimated useful lives (in years)	7 years
Patents [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired	$ 1
Estimated useful lives (in years)	10 years
Other Intangible Assets [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired	$ 9
Estimated useful lives (in years)	5 years

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Millions	Jul. 01, 2023	Dec. 31, 2022	Dec. 25, 2021
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	$ 820	$ 576	$ 613
Estimate of Fair Value Measurement [Member]
Debt Instrument, Fair Value Disclosure [Abstract]
Fair value of debt (including bank credit lines)	1,524	1,149
Fair value, measurements, recurring [Member] | Fair Value Measurement [Domain]
Assets [Abstract]
Total assets	28	27
Liabilities [Abstract]
Total liabilities	6	7
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	820	576
Fair value, measurements, recurring [Member] | Fair Value Measurement [Domain] | Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	21	23
Liabilities [Abstract]
Derivative contracts - liabilities	3	1
Fair value, measurements, recurring [Member] | Fair Value Measurement [Domain] | Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	4	4
Liabilities [Abstract]
Derivative contracts - liabilities	3	3
Fair value, measurements, recurring [Member] | Fair Value Measurement [Domain] | Total return swap [Member]
Assets [Abstract]
Total return swaps	3
Liabilities [Abstract]
Total return swaps		3
Fair value, measurements, recurring [Member] | Level 1 [Member] | Fair Value Measurement [Domain]
Assets [Abstract]
Total assets	0	0
Liabilities [Abstract]
Total liabilities	0	0
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] | Level 1 [Member] | Fair Value Measurement [Domain] | Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] | Level 1 [Member] | Fair Value Measurement [Domain] | Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] | Level 1 [Member] | Fair Value Measurement [Domain] | Total return swap [Member]
Assets [Abstract]
Total return swaps	0
Liabilities [Abstract]
Total return swaps		0
Fair value, measurements, recurring [Member] | Level 2 [Member] | Fair Value Measurement [Domain]
Assets [Abstract]
Total assets	28	27
Liabilities [Abstract]
Total liabilities	6	7
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] | Level 2 [Member] | Fair Value Measurement [Domain] | Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	21	23
Liabilities [Abstract]
Derivative contracts - liabilities	3	1
Fair value, measurements, recurring [Member] | Level 2 [Member] | Fair Value Measurement [Domain] | Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	4	4
Liabilities [Abstract]
Derivative contracts - liabilities	3	3
Fair value, measurements, recurring [Member] | Level 2 [Member] | Fair Value Measurement [Domain] | Total return swap [Member]
Assets [Abstract]
Total return swaps	3
Liabilities [Abstract]
Total return swaps		3
Fair value, measurements, recurring [Member] | Level 3 [Member] | Fair Value Measurement [Domain]
Assets [Abstract]
Total assets	0	0
Liabilities [Abstract]
Total liabilities	0	0
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	820	576
Fair value, measurements, recurring [Member] | Level 3 [Member] | Fair Value Measurement [Domain] | Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] | Level 3 [Member] | Fair Value Measurement [Domain] | Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] | Level 3 [Member] | Fair Value Measurement [Domain] | Total return swap [Member]
Assets [Abstract]
Total return swaps	$ 0
Liabilities [Abstract]
Total return swaps		$ 0

Debt - Revolving Credit Agreeme

Debt - Revolving Credit Agreement Narrative (Details) - USD ($)	6 Months Ended
	Jul. 01, 2023	Dec. 31, 2022
Revolving Credit Agreement [Member]
Line of Credit Facility [Line Items]
Line of credit initiation date	Aug. 20, 2021
Credit facility borrowing capacity	$ 1,000,000,000
Credit facility expiration date	Aug. 20, 2026
Line of credit interest rate	5.25%
Line of credit combined interest rate	6.05%
Debt instrument, basis spread on variable rate	0.80%
Borrowings	$ 250,000,000	$ 0
Outstanding letters of credit provided to third parties	9,000,000	9,000,000
Other Short-Term Credit Lines [Member]
Line of Credit Facility [Line Items]
Credit facility borrowing capacity	$ 426,000,000	$ 402,000,000

Debt - Other Short-Term Bank Cr

Debt - Other Short-Term Bank Credit Lines Narrative (Details) - USD ($)	Jul. 01, 2023	Dec. 31, 2022
Line of Credit Facility [Line Items]
Bank credit lines	$ 325,000,000	$ 103,000,000
Other Short-Term Credit Lines [Member]
Line of Credit Facility [Line Items]
Credit facility borrowing capacity	426,000,000	402,000,000
Bank credit lines	$ 75,000,000	$ 103,000,000
Weighted average interest rate on borrowings under credit lines at period end	12.09%	10.11%

Debt - Private Placement Facili

Debt - Private Placement Facilities Narrative (Details) - Private Placement Facilities [Member]	6 Months Ended
	Jul. 01, 2023 USD ($)
Debt Instrument [Line Items]
Number of companies included in private placement facilities	4
Debt instrument maximum borrowing capacity	$ 1,500,000,000
Debt instrument, maturity date	Oct. 20, 2026
Average term of issuances under private placement facilities	12 years
Weighted average interest rate at period end	3.65%
Minimum [Member]
Debt Instrument [Line Items]
Term of issuances under private placement facilities	5 years
Maximum [Member]
Debt Instrument [Line Items]
Term of issuances under private placement facilities	15 years

Debt - U.S. Trade Accounts Rece

Debt - U.S. Trade Accounts Receivable Securitization Narrative (Details) - U.S. Trade Accounts Receivable Securitization [Member]	6 Months Ended	12 Months Ended
	Jul. 01, 2023 USD ($) number	Dec. 31, 2022 USD ($)
Debt Instrument [Line Items]
Pricing commitment period	3 years
Debt Instrument, Maturity Date	Dec. 15, 2025
Debt instrument maximum borrowing capacity	$ 450,000,000
Long-term debt	$ 60,000,000	$ 330,000,000
Commitment fee for facility usage - facility limit less than fifty percent usage (as a percent)	0.30%
Commitment fee for facility usage - facility limit greater than or equal to fifty percent usage (as a percent)	0.35%
Number of banks as agents for debt instrument | number	2
Average Asset Backed Commercial Paper Rate [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate at period end	6.13%	5.33%
Debt instrument, variable rate basis at period end	5.38%	4.58%
Debt instrument, basis spread on variable rate	0.75%	0.75%

Debt - Term Loan Narrative (Det

Debt - Term Loan Narrative (Details) - Subsequent Event [Member] - Term Credit Agreement [Member]	Jul. 11, 2023 USD ($)
Line of Credit Facility [Line Items]
Debt face amount	$ 750,000,000
Debt term (in years)	3 years

Debt - Schedule of Bank Credit

Debt - Schedule of Bank Credit Lines (Details) - USD ($) $ in Millions	Jul. 01, 2023	Dec. 31, 2022
Line of Credit Facility [Line Items]
Bank Credit lines	$ 325	$ 103
Revolving Credit Agreement [Member]
Line of Credit Facility [Line Items]
Bank Credit lines	250	0
Other Short-Term Credit Lines [Member]
Line of Credit Facility [Line Items]
Bank Credit lines	$ 75	$ 103

Debt - Schedule of Long-term De

Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Millions	Jul. 01, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Finance lease obligations	$ 16	$ 10
Total	1,199	1,046
Less current maturities	(66)	(6)
Long-term debt	1,133	1,040
Private Placement Facilities [Member]
Debt Instrument [Line Items]
Long-term debt	1,074	699
U.S. Trade Accounts Receivable Securitization [Member]
Debt Instrument [Line Items]
Long-term debt	60	330
Various Collateralized and Uncollateralized Loans Payable with Interest in Varying Installments Through 2023 at Interest Rates Ranging from 0.00% to 3.65% at April 1, 2023 and Ranging from 0.00% to 3.50% at December 31, 2022 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 49	$ 7
Various Collateralized and Uncollateralized Loans Payable with Interest in Varying Installments Through 2023 at Interest Rates Ranging from 0.00% to 3.65% at April 1, 2023 and Ranging from 0.00% to 3.50% at December 31, 2022 [Member] | Minimum [Member]
Debt Instrument [Line Items]
Borrowing Rate	0%	0%
Various Collateralized and Uncollateralized Loans Payable with Interest in Varying Installments Through 2023 at Interest Rates Ranging from 0.00% to 3.65% at April 1, 2023 and Ranging from 0.00% to 3.50% at December 31, 2022 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Borrowing Rate	9.42%	3.50%

Debt - Schedule of Private Plac

Debt - Schedule of Private Placement Facility Borrowings (Details) - Private Placement Facilities [Member] - USD ($) $ in Millions	6 Months Ended
	Jul. 01, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Less: Deferred debt issuance costs	$ (1)
Total	$ 1,074	$ 699
Debt Instrument, Maturity Date	Oct. 20, 2026
Private Placement Facilities 1 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jan. 20, 2012
Long-term Debt, Gross	$ 50
Borrowing Rate	3.45%
Debt Instrument, Maturity Date	Jan. 20, 2024
Private Placement Facilities 2 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Dec. 24, 2012
Long-term Debt, Gross	$ 50
Borrowing Rate	3%
Debt Instrument, Maturity Date	Dec. 24, 2024
Private Placement Facilities 3 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jun. 16, 2017
Long-term Debt, Gross	$ 100
Borrowing Rate	3.42%
Debt Instrument, Maturity Date	Jun. 16, 2027
Private Placement Facilities 4 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Sep. 15, 2017
Long-term Debt, Gross	$ 100
Borrowing Rate	3.52%
Debt Instrument, Maturity Date	Sep. 15, 2029
Private Placement facilities 5 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jan. 02, 2018
Long-term Debt, Gross	$ 100
Borrowing Rate	3.32%
Debt Instrument, Maturity Date	Jan. 02, 2028
Private Placement Facilities 6 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Sep. 02, 2020
Long-term Debt, Gross	$ 100
Borrowing Rate	2.35%
Debt Instrument, Maturity Date	Sep. 02, 2030
Private Placement Facilities 7 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jun. 02, 2021
Long-term Debt, Gross	$ 100
Borrowing Rate	2.48%
Debt Instrument, Maturity Date	Jun. 02, 2031
Private Placement Facilities 8 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jun. 02, 2021
Long-term Debt, Gross	$ 100
Borrowing Rate	2.58%
Debt Instrument, Maturity Date	Jun. 02, 2033
Private Placement Facilities 9 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	May 04, 2023
Long-term Debt, Gross	$ 75
Borrowing Rate	4.79%
Debt Instrument, Maturity Date	May 04, 2028
Private Placement Facilities 10 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	May 04, 2023
Long-term Debt, Gross	$ 75
Borrowing Rate	4.84%
Debt Instrument, Maturity Date	May 04, 2030
Private Placement Facilities 11 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	May 04, 2023
Long-term Debt, Gross	$ 75
Borrowing Rate	4.96%
Debt Instrument, Maturity Date	May 04, 2033
Private Placement Facilities 12 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	May 04, 2023
Long-term Debt, Gross	$ 150
Borrowing Rate	4.94%
Debt Instrument, Maturity Date	May 04, 2033

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Millions	6 Months Ended
	Jul. 01, 2023	Jun. 25, 2022	Dec. 31, 2022
Income Tax Examination [Line Items]
Effective tax rate	22.80%	23.90%
Tax interest expense (credit)	$ 1	$ 0
Other Liabilities [Member]
Income Tax Examination [Line Items]
Unrecognized tax benefits	103		$ 94
Unrecognized tax benefits that would affect the effective tax rate if recognized	88		80
Total interest	$ 14		$ 12

Plan of Restructuring - Narrati

Plan of Restructuring - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jun. 25, 2022	Jul. 01, 2023	Jun. 25, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 18,000,000	$ 0	$ 48,000,000	$ 0

Plan of Restructuring - Schedul

Plan of Restructuring - Schedule of Restructuring Costs (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jun. 25, 2022	Jul. 01, 2023	Jun. 25, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	$ 18,000,000	$ 0	$ 48,000,000	$ 0
Severance and Employee-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	14,000,000		34,000,000
Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	3,000,000		10,000,000
Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1,000,000		3,000,000
Disposal of Business [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs			1,000,000
Health Care Distribution [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	16,000,000		42,000,000
Health Care Distribution [Member] | Severance and Employee-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	13,000,000		30,000,000
Health Care Distribution [Member] | Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	2,000,000		9,000,000
Health Care Distribution [Member] | Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1,000,000		2,000,000
Health Care Distribution [Member] | Disposal of Business [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs			1,000,000
Technology and Value-Added Services [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	2,000,000		6,000,000
Technology and Value-Added Services [Member] | Severance and Employee-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1,000,000		4,000,000
Technology and Value-Added Services [Member] | Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1,000,000		1,000,000
Technology and Value-Added Services [Member] | Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	$ 0		1,000,000
Technology and Value-Added Services [Member] | Disposal of Business [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs			$ 0

Plan of Restructuring - Sched_2

Plan of Restructuring - Schedule of Restructuring Reserve by Segment (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jun. 25, 2022	Jul. 01, 2023	Jun. 25, 2022
Restructuring Cost and Reserve [Line Items]
Balance, beginning			$ 24,000,000
Restructuring costs	$ 18,000,000	$ 0	48,000,000	$ 0
Non-cash asset impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets			(10,000,000)	$ 0
Cash payments and other adjustments			(29,000,000)
Balance, ending	33,000,000		33,000,000
Health Care Distribution [Member]
Restructuring Cost and Reserve [Line Items]
Balance, beginning			21,000,000
Restructuring costs	16,000,000		42,000,000
Non-cash asset impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets			(9,000,000)
Cash payments and other adjustments			(24,000,000)
Balance, ending	30,000,000		30,000,000
Technology and Value-Added Services [Member]
Restructuring Cost and Reserve [Line Items]
Balance, beginning			3,000,000
Restructuring costs	2,000,000		6,000,000
Non-cash asset impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets			(1,000,000)
Cash payments and other adjustments			(5,000,000)
Balance, ending	$ 3,000,000		$ 3,000,000

Legal Proceedings - Narrative (

Legal Proceedings - Narrative (Details) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2023 USD ($) claims	Jun. 25, 2022 USD ($)	Jul. 01, 2023 USD ($) claims	Jun. 25, 2022 USD ($)
Loss Contingency, Information about Litigation Matters [Abstract]
Revenues	$ 3,100	$ 3,030	$ 6,160	$ 6,209
Maximum [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Pending Claims, Number | claims	175		175
Actions Consolidated in the MultiDistrict Litigation [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Maximum sales of opioids in North America during the year, percentage			0.20%
Actions Consolidated in the MultiDistrict Litigation [Member] | Continuing Operations [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Revenues			$ 12,600
Other Hospitals Located throughout Florida [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Number of plaintiffs			38

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jun. 25, 2022	Jul. 01, 2023	Jun. 25, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average period of recognition for unrecognized compensation costs on nonvested awards (in years)			2 years 4 months 24 days
Grants in period (in shares)			0
Total unrecognized compensation cost related to non-vested awards	$ 107		$ 107
Expected life of options (years)			6 years
After-tax share-based compensation (credit) expense	11	$ 12	$ 19	$ 21
Pre-tax share-based compensation (Credit) expense	$ 14	$ 15	$ 24	$ 27
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)			3 years
Percentage of stock options vest per year			33.33%
Expiration period (in years)			10 years
Time-Based Restricted Stock/Restricted Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)			4 years
Time-Based Restricted Stock/Restricted Units [Member] | 2015 Non-Employee Director Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)			12 months
Performance-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)			3 years

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity under the Plans (Details) - USD ($) $ / shares in Units, $ in Millions	6 Months Ended
	Jul. 01, 2023
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period (in shares)	1,117,574
Granted (in shares)	0
Exercised (in shares)	(17,905)
Forfeited (in shares)	(7,541)
Outstanding at end of period (in shares)	1,092,128
Weighted Average Exercise Price Per Share [Abstract]
Outstanding at beginning of period (in dollars per share)	$ 71.38
Exercised (in dollars per share)	62.71
Forfeited (in dollars per share)	78.22
Outstanding at end of period (in dollars per share)	$ 71.48
Outstanding at end of period, Weighted Average Remaining Contractual Life in Years	8 years 1 month 6 days
Outstanding at end of period, Aggregate Intrinsic Value	$ 12
Options exercisable (in shares)	568,623
Weighted average exercise price, options exercisable (in dollars per share)	$ 68.25

Stock-Based Compensation - Intr

Stock-Based Compensation - Intrinsic Values (Details) $ / shares in Units, $ in Millions	6 Months Ended
	Jul. 01, 2023 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options | shares	517,576
Weighted Average Exercise Price | $ / shares	$ 75.12
Weighted Average Remaining Contractual Life (in years)	8 years 3 months 18 days
Intrinsic Value Per Share | $	$ 4

Stock-Based Compensation - Stat

Stock-Based Compensation - Status of Unvested RSUs (Details)	6 Months Ended
	Jul. 01, 2023 $ / shares shares
Time-Based Restricted Stock/Restricted Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance outstanding (in shares) | shares	1,756,044
Granted (in shares) | shares	407,570
Vested (in shares) | shares	(406,604)
Forfeited (in shares) | shares	(54,420)
Ending balance outstanding (in shares) | shares	1,702,590
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance outstanding (in dollars per share)	$ 66.59
Granted (in dollars per share)	77.70
Vested (in dollars per share)	61.66
Forfeited (in dollars per share)	71.07
Ending balance outstanding (in dollars per share)	70.34
Aggregate intrinsic value	$ 81.10
Performance-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance outstanding (in shares) | shares	520,916
Granted (in shares) | shares	530,224
Vested (in shares) | shares	(630,294)
Forfeited (in shares) | shares	(49,524)
Ending balance outstanding (in shares) | shares	371,322
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance outstanding (in dollars per share)	$ 60.23
Granted (in dollars per share)	78.38
Vested (in dollars per share)	60.64
Forfeited (in dollars per share)	76.09
Ending balance outstanding (in dollars per share)	69.62
Aggregate intrinsic value	$ 81.10

Redeemable Noncontrolling Int_3

Redeemable Noncontrolling Interests - Components of the Change in Redeemable Noncontrolling Interests (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jul. 01, 2023	Jun. 25, 2022	Jul. 01, 2023	Jun. 25, 2022	Dec. 31, 2022
Components of the change in the redeemable noncontrolling interests [Abstract]
Balance, beginning of period			$ 576	$ 613	$ 613
Decrease in redeemable noncontrolling interests due to acquisitions of noncontrolling interesta in subsidiaries			(13)		(31)
Increase in redeemable noncontrolling interests due to business acquisitions			240		4
Net income attributable to redeemable noncontrolling interests	$ 5	$ 5	9	9	21
Dividends declared			(7)		(21)
Effect of foreign currency translation gain (loss) attributable to redeemable noncontrolling interests	(1)	$ (8)	1	$ 7	(6)
Change in fair value of redeemable securities			14		(4)
Balance, end of period	$ 820		$ 820		$ 576

Comprehensive Income - Accumula

Comprehensive Income - Accumulated Other Comprehensive Income and Comprehensive Income Components (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jun. 25, 2022	Jul. 01, 2023	Jun. 25, 2022	Dec. 31, 2022
Attributable to Redeemable noncontrolling interests:
Foreign currency translation adjustment	$ (36)		$ (36)		$ (37)
Attributable to noncontrolling interests:
Foreign currency translation adjustment	(1)		(1)		(1)
Attributable to Henry Schein, Inc.:
Foreign currency translation adjustment	(209)		(209)		(236)
Unrealized gain from foreign currency hedging activities	1		1		5
Pension adjustment loss	(2)		(2)		(2)
Accumulated other comprehensive loss	(210)		(210)		(233)
Total Accumulated other comprehensive loss	(247)		(247)		$ (271)
Components of Comprehensive Income
Net Income (loss)	148	$ 167	276	$ 353
Foreign currency translation gain (loss)	3	(90)	28	(87)
Tax effect	0	0	0	0
Foreign currency translation gain (loss)	3	(90)	28	(87)
Unrealized gain (loss) from foreign currency hedging activities	(2)	10	(6)	12
Tax effect	1	(2)	2	(3)
Unrealized gain (loss) from foreign currency hedging activities	(1)	8	(4)	9
Comprehensive income	$ 150	$ 85	$ 300	$ 275

Comprehensive Income - Total Co

Comprehensive Income - Total Comprehensive Income, Net of Applicable Taxes (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jun. 25, 2022	Jul. 01, 2023	Jun. 25, 2022
Comprehensive Income Net Of Applicable Taxes [Abstract]
Comprehensive income attributable to Henry Schein, Inc.	$ 143	$ 87	$ 284	$ 271
Comprehensive income attributable to noncontrolling interests	3	1	6	2
Comprehensive income attributable to Redeemable noncontrolling interests	4	(3)	10	2
Comprehensive income	$ 150	$ 85	$ 300	$ 275

Earnings Per Share - Reconcilia

Earnings Per Share - Reconciliation of Shares used in Calculating Earnings per Share Basic and Diluted (Details) - shares	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jun. 25, 2022	Jul. 01, 2023	Jun. 25, 2022
Weighted-average common shares outstanding:
Basic (in shares)	130,905,899	137,350,488	131,136,450	137,323,076
Effect of dilutive securities:
Stock options and restricted stock units	967,275	1,518,576	1,329,299	1,732,129
Diluted (in shares)	131,873,174	138,869,064	132,465,749	139,055,205

Earnings Per Share - Schedule o

Earnings Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jun. 25, 2022	Jul. 01, 2023	Jun. 25, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from EPS computation	445,407	475,239	446,760	476,429
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from EPS computation	426,002	423,786	427,355	250,226
Restricted Stock Units [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from EPS computation	19,405	51,453	19,405	226,203

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jun. 25, 2022	Jul. 01, 2023	Jun. 25, 2022
Supplemental Cash Flow Information [Abstract]
Interest			$ 32	$ 17
Income taxes			118	165
Non-cash net unrealized gains related to foreign currency hedging activities	$ (2)	$ 10	$ (6)	$ 12

Related Party Transactions - Na

Related Party Transactions - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jun. 25, 2022	Jul. 01, 2023	Jun. 25, 2022	Dec. 31, 2022
Related Party Transaction [Line Items]
Current operating lease liabilities	$ 74		$ 74		$ 73
Noncurrent operating lease liabilities	284		$ 284		275
Equity Method Investee [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Description of Transaction			During our normal course of business, we have interests in entities that we account for under the equity accounting method.
Due to related party	5		$ 5		6
Due from related party	33		33		36
Revenue from Related Parties	11	$ 11	23	$ 23
Related Party Transaction, Purchases from Related Party	3	3	5	6
Internet Brands Inc [Member]
Related Party Transaction [Line Items]
Distributions to noncontrolling shareholders			$ 27
Internet Brands Inc [Member] | Royalty Agreements [Member]
Related Party Transaction [Line Items]
Period Covered By Agreement			10 years
Related party agreement amount			$ 31
Related Party Transaction, Expenses from Transactions with Related Party	8	$ 8	16	$ 16
Related Party Transaction, Due from (to) Related Party	10		10		$ 9
Employees and Minority Shareholders [Member]
Related Party Transaction [Line Items]
Current operating lease liabilities	6		6
Noncurrent operating lease liabilities	$ 25		$ 25
Employees and Minority Shareholders [Member] | Operating Lease Liabilities, Current [Member] | Related Party Concentration Risk[Member]
Related Party Transaction [Line Items]
Concentration risk percentage			7.60%
Employees and Minority Shareholders [Member] | Operating Lease Liabilities, Non-Current [Member] | Related Party Concentration Risk[Member]
Related Party Transaction [Line Items]
Concentration risk percentage			9%
Employees and Minority Shareholders [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Remaining operating lease term	1 year		1 year
Employees and Minority Shareholders [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Remaining operating lease term	14 years		14 years